COL4A5 and Alport syndrome: Minnelide, its water-soluble prodrug, provides a promising alternative.<h4>Objective</h4>This study investigated the therapeutic potential and mechanisms of Minnelide in a female Col4a5 (X + X-) Alport syndrome mouse model.<h4>Methods</h4>Mice were treated with Minnelide or vehicle for 3 months.